What Is Glycemic Control?
Glycemic control refers to the body's capacity to maintain blood glucose levels within appropriate physiologic ranges. In healthy individuals, fasting glucose lies between 70 and 99 mg/dL, and postprandial glucose rarely exceeds 140 mg/dL.
In type 2 diabetes mellitus (T2D), insulin resistance and progressive dysfunction of pancreatic beta cells compromise this balance, resulting in chronic hyperglycemia. Glycated hemoglobin (HbA1c) is the main marker of long-term glycemic control, reflecting the average glycemia of the last 90 to 120 days.
Maintaining HbA1c below 7% significantly reduces the risk of microvascular complications (retinopathy, nephropathy, neuropathy) and, to a lesser extent, macrovascular complications (myocardial infarction, stroke, peripheral arterial disease). Pursuit of appropriate glycemic targets is central in diabetes management.
HbA1c < 7%
Recommended target for most adults with type 2 diabetes, associated with lower risk of microvascular complications.
Fasting Glucose
Target between 80 and 130 mg/dL for most patients. Values persistently above 130 mg/dL indicate the need for therapeutic adjustment.
Postprandial Glucose
Target below 180 mg/dL two hours after the meal. Postprandial peaks contribute independently to cardiovascular risk.
Pathophysiology of Poor Glycemic Control
Type 2 diabetes results from the interaction between insulin resistance in peripheral tissues (muscle, liver, adipose tissue) and progressive failure of beta cells of the pancreas. At the time of diagnosis, an estimated 50% of beta cell function is already compromised.
Insulin resistance in the liver increases hepatic glucose production, especially during the overnight fast. In skeletal muscle, it impairs glucose uptake mediated by the GLUT4 transporter. In adipose tissue, it promotes excessive lipolysis with release of free fatty acids, which further worsen insulin resistance.
Why Is Poor Glycemic Control Dangerous?
Chronic hyperglycemia activates mechanisms of tissue damage: formation of advanced glycation end products (AGEs), activation of the polyol pathway, oxidative stress, and endothelial dysfunction. These processes progressively damage blood vessels and peripheral nerves.
Glycemic variability (frequent oscillations between hypo- and hyperglycemia) also contributes to vascular damage, independently of HbA1c. Continuous glucose monitoring has revealed that postprandial peaks and nocturnal hypoglycemias are more prevalent than HbA1c alone suggests.
Symptoms of Poor Glycemic Control
Hyperglycemia can be silent for years. When symptoms appear, they generally indicate glycemia persistently above 180-200 mg/dL. Recognizing early signs allows intervention before complications set in.
Signs of Poor Glycemic Control
- 01
Polyuria (excessive urination)
Increased urinary volume caused by osmotic glycosuria when blood glucose exceeds the renal threshold (~180 mg/dL).
- 02
Polydipsia (excessive thirst)
Intense thirst compensating for fluid loss in the urine. May lead to intake of more than 3-4 liters per day.
- 03
Unexplained weight loss
Despite preserved or increased appetite, the inability to use glucose appropriately leads to muscle and fat catabolism.
- 04
Persistent fatigue
Direct consequence of the inability of cells to use glucose as an energy source, in addition to dehydration.
- 05
Blurred vision
Hyperglycemia alters the osmolarity of the lens, causing edema and refractive change. It is reversible with glycemic control.
- 06
Slow wound healing
Hyperglycemia compromises immune function, peripheral vascularization, and the synthesis of collagen needed for tissue repair.
- 07
Tingling in the extremities
Paresthesias in hands and feet indicate early diabetic neuropathy from damage to small nerve fibers.
- 08
Recurrent infections
Vaginal candidiasis, recurrent urinary infections, and skin infections are more frequent in uncontrolled diabetes.
Diagnosis and Monitoring
The diagnosis of type 2 diabetes and the assessment of glycemic control are based on standardized laboratory tests. Confirmation requires at least two abnormal results or one abnormal result accompanied by classic symptoms.
🏥Diagnostic Criteria for Diabetes Mellitus
Fonte: Brazilian Diabetes Society (SBD) / ADA 2024
Diagnostic Tests
- 1.Fasting glucose ≥ 126 mg/dL (8-hour fast)
- 2.HbA1c ≥ 6.5% (NGSP-standardized method)
- 3.2-h post-OGTT glucose ≥ 200 mg/dL (oral test with 75 g of glucose)
- 4.Random glucose ≥ 200 mg/dL with classic symptoms
Glycemic Control Targets (Adults with T2D)
- 1.HbA1c: < 7% for most adults; individualized for older adults and frail patients
- 2.Pre-prandial glucose: 80-130 mg/dL
- 3.Postprandial glucose (2 h): < 180 mg/dL
- 4.Time in range (TIR): > 70% between 70-180 mg/dL on continuous monitoring
GLYCEMIC MONITORING TOOLS
| TOOL | WHAT IT MEASURES | ADVANTAGES | LIMITATIONS |
|---|---|---|---|
| HbA1c | Average glycemia of 90-120 days | Standardized, widely available | Does not capture glycemic variability or hypoglycemias |
| Capillary glucose (fingerstick) | Glucose at the moment of measurement | Immediate, accessible, low cost | Snapshot only; requires multiple daily measurements |
| Continuous glucose monitor (CGM) | Interstitial glucose every 5 min | Trends, alerts, TIR, variability | High cost; calibration required in some models |
| Fructosamine | Average glycemia of 2-3 weeks | Useful in anemias that alter HbA1c | Less standardized; few laboratories perform it |
Complications of Poor Glycemic Control
Diabetes complications are classified as microvascular and macrovascular. The relationship between HbA1c level and the risk of complications is continuous: each 1% reduction in HbA1c is associated with a 21% decrease in the risk of microvascular complications.
MICROVASCULAR AND MACROVASCULAR COMPLICATIONS OF DIABETES
| CATEGORY | COMPLICATION | PREVALENCE | MAIN MECHANISM |
|---|---|---|---|
| Microvascular | Diabetic retinopathy | 30-40% after 20 years | Damage to retinal microvasculature by AGEs and oxidative stress |
| Microvascular | Diabetic nephropathy | 20-30% of patients | Thickening of the glomerular basement membrane and mesangial sclerosis |
| Microvascular | Diabetic neuropathy | 30-50% of patients | Axonal damage from glucotoxicity, ischemia of the vasa nervorum |
| Macrovascular | Coronary artery disease | 2-4x higher risk | Accelerated atherosclerosis, endothelial dysfunction, prothrombotic state |
| Macrovascular | Ischemic stroke | 2x higher risk | Atherosclerosis of carotid and cerebral arteries |
| Macrovascular | Peripheral arterial disease | 15-20% of patients | Lower-limb ischemia, risk of amputation |
Conventional Treatment
The management of type 2 diabetes is multifactorial, combining lifestyle changes (diet and physical exercise), pharmacotherapy, and regular monitoring. Treatment is individualized according to HbA1c, comorbidities, cardiovascular risk, and patient preferences.
Metformin remains the first-line pharmacologic agent for most patients. In recent decades, new therapeutic classes such as SGLT2 inhibitors and GLP-1 agonists have transformed treatment by offering cardiovascular and renal benefits beyond glycemic control.
MAIN DRUG CLASSES FOR TYPE 2 DIABETES
| CLASS | MECHANISM | HBA1C REDUCTION | ADDITIONAL EFFECTS |
|---|---|---|---|
| Metformin | Reduces hepatic glucose production; improves insulin sensitivity | 1.0-1.5% | Low cost; weight-neutral; possible cardiovascular benefit |
| SGLT2 inhibitors (empagliflozin, dapagliflozin) | Block renal glucose reabsorption | 0.5-1.0% | Cardiovascular and renal protection; weight loss of 2-3 kg |
| GLP-1 agonists (semaglutide, liraglutide) | Stimulate insulin secretion; suppress glucagon; delay gastric emptying | 1.0-1.8% | Significant weight loss (4-7 kg); cardiovascular protection |
| DPP-4 inhibitors (sitagliptin, vildagliptin) | Prolong action of endogenous incretins | 0.5-0.8% | Well tolerated; weight-neutral |
| Sulfonylureas (gliclazide, glimepiride) | Stimulate insulin secretion by beta cells | 1.0-1.5% | Low cost; risk of hypoglycemia and weight gain |
| Insulin (basal, bolus, premixed) | Direct hormonal replacement | 1.5-3.5% | No efficacy ceiling; risk of hypoglycemia and weight gain |
Lifestyle Changes
A balanced diet and regular physical exercise are irreplaceable pillars of treatment. Weight loss of 5-10% significantly improves insulin sensitivity, reduces HbA1c by 0.5-1.0%, and decreases the need for medications.
Aerobic exercise (150 minutes/week of moderate intensity) and resistance exercise (2-3 weekly sessions) improve muscle glucose uptake independently of insulin, via GLUT4 translocation mediated by muscle contraction.
Acupuncture as Complementary Therapy
Acupuncture has been investigated as a complementary therapy in the management of type 2 diabetes, always associated with conventional treatment (diet, exercise, medication). Growing evidence suggests that acupuncture can improve metabolic parameters through multiple physiologic mechanisms.
It is essential to emphasize that acupuncture does not replace prescribed medication, diet, or physical exercise. It acts as an adjuvant, potentiating the effects of conventional treatment and helping in the management of associated symptoms that affect quality of life.
Mechanisms of Action
The effects of acupuncture on glucose metabolism are attributed, in experimental models and clinical studies, to neuroendocrine modulation. It is proposed that stimulation of specific points may activate the autonomic nervous system, particularly the parasympathetic (vagus) branch, involved in the regulation of insulin secretion and hepatic glucose production — but the magnitude and clinical relevance of these mechanisms are still under investigation.
Studies in experimental models show that electroacupuncture can improve insulin sensitivity in peripheral tissues through activation of the AMPK pathway (AMP-activated protein kinase) in skeletal muscle, increasing translocation of the GLUT4 transporter to the cell membrane.
Other mechanisms under investigation include: reduction of systemic inflammatory markers (TNF-alpha, IL-6), modulation of the hypothalamic-pituitary-adrenal axis (reducing chronic cortisol that worsens insulin resistance), improved beta cell function, and regulation of the gut microbiota.
Autonomic Regulation
Studies suggest that vagal stimulation may improve parasympathetic tone, with possible impact on insulin secretion and hepatic glucose production — a mechanism still under investigation.
Insulin Sensitivity
Activation of the AMPK pathway and increased GLUT4 expression in skeletal muscle improve peripheral glucose uptake.
Reduction of Inflammation
Decrease of pro-inflammatory cytokines (TNF-alpha, IL6) that contribute to insulin resistance in adipose and muscle tissue.
Scientific Evidence
Some trials and systematic reviews suggest that acupuncture, as an adjuvant to conventional treatment, may be associated with modest reductions in HbA1c and fasting glucose in patients with T2D. The Cochrane reviews (Chen 2019) and high-quality independent meta-analyses still consider the evidence insufficient for a firm conclusion; the magnitude of clinical effect and reproducibility require confirmation in robust trials.
Another updated meta-analysis (Jiang et al., 2026) confirmed that adjuvant acupuncture improved parameters of glucose metabolism, with more consistent effects on fasting glucose and insulin resistance (HOMA-IR index). Some studies suggest a greater magnitude of effect with low-frequency electroacupuncture (2-4 Hz), although comparative evidence between protocols is still insufficient.
Studies of microcirculation have shown that acupuncture can improve microvascular perfusion in patients with diabetic complications, such as diabetic foot syndrome, suggesting a role in the prevention of peripheral complications.
Safety and Integration with Standard Treatment
Medical acupuncture is considered safe as a complementary therapy in diabetes. Adverse effects are minimal and generally limited to local hematomas at the insertion points. There are no known interactions with antidiabetic medications (metformin, insulin, SGLT2 inhibitors, or GLP-1 agonists).
The medical acupuncturist should pay attention to the patient's glycemic monitoring, since improvement in insulin sensitivity may, in some cases, require adjustment of medication doses in coordination with the endocrinologist, especially in patients on sulfonylureas or insulin (risk of hypoglycemia).
Prognosis
The prognosis of type 2 diabetes depends directly on the quality of glycemic control over time. The UKPDS study showed that early intensive control confers lasting benefits — the so-called "legacy effect" — even after decades of follow-up.
With appropriate, multifactorial treatment (glycemic, blood pressure, lipid, and smoking cessation control), patients with T2D can have life expectancy close to that of the general population. The key is early intervention and sustained adherence to treatment.
Course of Type 2 Diabetes Management
Phase 1
0-3 monthsDiagnosis and Lifestyle
Diagnostic confirmation, patient education, initiation of diet and exercise. Metformin as first-line pharmacotherapy. Establish individualized HbA1c targets.
Phase 2
3-6 monthsTherapeutic Optimization
Assessment of response to metformin (HbA1c at 3 months). Addition of a second agent if target not reached. Consider SGLT2i or GLP-1RA in patients with cardiovascular risk. Initiate acupuncture as adjuvant.
Phase 3
6-12 monthsIntensification and Screening
Screening for complications (fundus examination, microalbuminuria, foot evaluation). Therapeutic adjustments according to response. Maintenance of acupuncture sessions if benefit documented.
Phase 4
ContinuousLong-Term Follow-Up
Continuous monitoring of HbA1c (quarterly to semi-annually), renal function, lipid profile. Reevaluation of targets in older or comorbid patients. Maintenance of lifestyle and pharmacologic treatment.
Myths and Facts
Myth vs. Fact
Acupuncture can replace insulin or metformin in diabetes.
Acupuncture is exclusively complementary. It should never replace prescribed medications, diet, or exercise. Its efficacy is as an adjuvant to conventional treatment.
Type 2 diabetes always needs insulin from the start.
Most patients with T2D start treatment with lifestyle changes and metformin. Insulin is reserved for cases with advanced beta cell failure or when other medications do not reach the targets.
If glycemia is controlled, I can stop treatment.
Type 2 diabetes is a chronic and progressive disease. Discontinuing treatment leads to the return of hyperglycemia in most cases. Maintaining treatment prevents long-term complications.
Natural teas and supplements control diabetes without medication.
No tea or supplement has sufficient evidence to replace antidiabetic medications. Some may interfere with the medication. Always inform the physician about any supplement used.
When to Seek Medical Help
Frequently Asked Questions about Glycemic Control and Acupuncture
Glycemic control is the ability to maintain blood glucose levels within appropriate ranges. In type 2 diabetes, the main marker is glycated hemoglobin (HbA1c), which reflects the average glycemia of the last 3 months. Maintaining HbA1c below 7% reduces by up to 21% the risk of microvascular complications (retinopathy, nephropathy, neuropathy) for each 1% reduction. Chronic poor control leads to progressive vascular and nerve damage.
No. Acupuncture is exclusively a complementary therapy and should never replace insulin, metformin, or other medications prescribed by the endocrinologist. It works as an adjuvant, potentiating the effect of conventional treatment. Studies show that acupuncture may contribute additional reductions of 0.4-0.7% in HbA1c when combined with medication. Discontinuing medications without medical guidance can lead to serious complications.
Acupuncture acts through multiple physiologic mechanisms: improvement of insulin sensitivity through activation of the AMPK pathway and increased GLUT4 translocation in muscle; modulation of the autonomic nervous system via vagal stimulation, optimizing insulin secretion; reduction of systemic inflammatory markers (TNF-alpha, IL-6) that worsen insulin resistance; and modulation of the hypothalamic-pituitary-adrenal axis, reducing chronic cortisol.
Protocols with the best results in clinical studies use 2-3 sessions per week in the first 4 weeks, followed by 1-2 sessions per week for an additional 8 to 20 weeks. Response is assessed by HbA1c every 3 months. The medical acupuncturist adjusts the frequency according to individual response. Patients with long-standing diabetes or with multiple comorbidities may require more prolonged protocols.
HbA1c reflects the average glycemia of the last 90-120 days and is the main long-term control indicator (target: < 7%). Fasting glucose measures the glucose level after 8 hours without eating (target: 80-130 mg/dL), reflecting mainly nocturnal hepatic glucose production. Postprandial glucose is measured 2 hours after the meal (target: < 180 mg/dL) and assesses the insulin response to the carbohydrate load. Each measurement captures different aspects of glucose metabolism.
Yes, medical acupuncture is safe for patients on insulin. There are no known interactions between acupuncture and antidiabetic medications. Adverse effects are minimal — generally limited to small hematomas at the insertion points. The medical acupuncturist should pay attention to glycemic monitoring, since improved insulin sensitivity may eventually require dose adjustment, in coordination with the endocrinologist, to avoid hypoglycemia.
Complications are divided into microvascular and macrovascular. Microvascular include retinopathy (30-40% of patients after 20 years, possibly leading to blindness), nephropathy (20-30%, possibly progressing to dialysis), and neuropathy (30-50%, with pain, tingling, and risk of amputation). Macrovascular include coronary disease (2-4 times higher risk of myocardial infarction), stroke, and peripheral arterial disease. Strict control of HbA1c, blood pressure, and cholesterol significantly reduces these risks.
Growing evidence suggests that acupuncture can help in the management of diabetic neuropathy symptoms, especially neuropathic pain and tingling. Proposed mechanisms include improved microcirculation in peripheral nerves, modulation of nociceptive transmission, and reduction of perineural inflammation. Studies on microcirculation in diabetic foot syndrome also show benefits. Treatment of neuropathy with acupuncture is always complementary to optimization of glycemic control.
The two most impactful interventions are balanced diet and regular exercise. A 5-10% reduction in body weight significantly improves insulin sensitivity and may reduce HbA1c by 0.5-1.0%. Aerobic exercise (150 minutes/week) and resistance exercise (2-3 sessions/week) improve glucose uptake by muscle. The diet should prioritize fiber, protein, and healthy fats, limiting refined carbohydrates. Adequate sleep and stress management also directly influence glycemia.
Acupuncture may be considered when: the patient does not reach HbA1c targets despite optimized conventional treatment; when there are associated symptoms that affect quality of life (neuropathy, chronic pain, insomnia, stress); or when an integrative complementary approach is sought. The medical acupuncturist evaluates the individual indication and coordinates with the endocrinologist to ensure safety and efficacy. The ideal moment is as part of a comprehensive therapeutic plan, not as a last resort.
Related Reading
Deepen your knowledge with related articles